Botanee Group Valuation Multiples

Discover Botanee Group's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Flyco, Zydus Wellness, Anhui Anke Biotechnology, Emami and more.

Botanee Group Overview

About Botanee Group

Yunnan Botanee Bio-Technology Group Co Ltd manufactures and sells skin care and cosmetics. The company develops and sells skin care products such as creams, lotions, masks, essences, and makeup items like BB creams, isolation creams, and removers. It also produces skin care-related medical devices, including hyaluronic acid repair films and dressings, used for protecting sensitive skin and post-procedure care.


Founded

2010

HQ

China

Employees

4.0K

Financials (LTM)

Revenue: $841M
EBITDA: $130M

EV

$1.5B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Botanee Group Financials

Botanee Group reported last 12-month revenue of $841M and EBITDA of $130M.

In the same LTM period, Botanee Group generated $625M in gross profit, $130M in EBITDA, and $84M in net income.

Revenue (LTM)


Botanee Group P&L

In the most recent fiscal year, Botanee Group reported revenue of $791M and EBITDA of $125M.

Botanee Group is profitable as of last fiscal year, with gross margin of 74%, EBITDA margin of 16%, and net margin of 9%.

See analyst estimates for Botanee Group
LTMLast FY202320242025202620272028
Revenue$841M$791M$815M$847M$791M
Gross Profit$625M$589M$603M$625M$589M
Gross Margin74%74%74%74%74%
EBITDA$130M$125M$149M$120M$125M
EBITDA Margin15%16%18%14%16%
EBIT Margin12%11%15%10%11%
Net Profit$84M$75M$112M$74M$75M
Net Margin10%9%14%9%9%

Financial data powered by Morningstar, Inc.

Botanee Group Stock Performance

Botanee Group has current market cap of $2B, and enterprise value of $1.5B.

Market Cap Evolution


Botanee Group's stock price is $4.66.

Botanee Group share price increased by 0.5% in the last 30 days, and decreased by 28.4% in the last year.

Botanee Group has an EPS (earnings per share) of $0.18.

See more trading valuation data for Botanee Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1.5B$2B0.0%0.5%-22.0%-28.4%$0.18

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Botanee Group Valuation Multiples

Botanee Group trades at 1.8x EV/Revenue multiple, and 11.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Botanee Group

EV / Revenue (LTM)


Botanee Group Financial Valuation Multiples

As of July 19, 2026, Botanee Group has market cap of $2B and EV of $1.5B.

Botanee Group has a P/E ratio of 23.5x.

LTMLast FY202320242025202620272028
EV/Revenue1.8x1.9x1.8x1.8x1.9x
EV/EBITDA11.4x11.9x10.0x12.4x11.9x
EV/EBIT14.8x17.0x12.0x17.5x17.6x
EV/Gross Profit2.4x2.5x2.5x2.4x2.5x
P/E23.5x26.4x17.7x26.6x26.4x
EV/FCF32.3x13.5x30.0x31.8x20.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Botanee Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Botanee Group Margins & Growth Rates

Botanee Group grew revenue by 12% and EBITDA by 12% in the last fiscal year.

In the most recent fiscal year, Botanee Group reported gross margin of 74%, EBITDA margin of 16%, and net margin of 9%.

See estimated margins and future growth rates for Botanee Group

Botanee Group Margins

Last FY202420252026202720282029
Gross Margin74%74%74%74%
EBITDA Margin16%14%16%16%
EBIT Margin11%10%11%13%
Net Margin9%9%9%11%
FCF Margin14%6%9%(1%)

Botanee Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%4%(7%)12%
Gross Profit Growth12%4%(6%)12%
EBITDA Growth12%(19%)4%12%
EBIT Growth27%(32%)(0%)31%
Net Profit Growth25%(34%)1%25%
FCF Growth(106%)(6%)56%(109%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Botanee Group Operational KPIs

Botanee Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Botanee Group's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Botanee Group's Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Botanee Group
LTMLast FY202320242025202620272028
Rule of 4027%28%---
Bessemer Rule of X44%46%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue50%50%40%40%41%
G&A Expenses to Revenue9%10%3%4%4%
R&D Expenses to Revenue4%4%5%5%4%
Opex to Revenue-64%59%64%64%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Botanee Group Competitors

Botanee Group competitors include Flyco, Zydus Wellness, Anhui Anke Biotechnology, Emami, Harbin Fuerjia Technology, Alicorp, Softcare, Qingdao Baheal Medical, Kolmar Korea and Blue Moon Group.

Most Botanee Group public comparables operate across Health & Beauty.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Flyco2.9x2.8x14.7x13.7x
Zydus Wellness5.5x5.0x42.5x36.5x
Anhui Anke Biotechnology4.6x4.4x12.6x12.3x
Emami4.5x4.4x16.5x17.0x
Harbin Fuerjia Technology5.6x4.9x16.3x15.4x
Alicorp0.9x0.9x6.4x6.1x
Softcare3.1x-11.2x-
Qingdao Baheal Medical1.7x1.7x13.5x14.5x

This data is available for Pro users. Sign up to see all Botanee Group competitors and their valuation data.

Start Free Trial

Investments by Botanee Group

Botanee Group has invested in 4 companies to date.

Latest investment by Botanee Group was on December 10th 2025. Botanee Group invested in Zisong Medical in their Seed round.

See VC round multiples

Latest Investments by Botanee Group

Zisong Medical
Weimai Medical
Weimu Medical
Ruishi Technology
Description
Zisong Medical is a manufacturer of advanced photoelectric equipment for medical aesthetics, delivering devices that improve treatment efficacy in the beauty industry.
-
Weimu Medical is a developer of high-end interventional medical devices.
Ruishi Technology is a developer of medical devices for myopia prevention and control. China-based, the company offers specialized products accessible through svision100.com to address rising vision health concerns in pediatric populations.
HQ CountryChinaChinaChinaChina
HQ City
-
-
Shanghai
Shanghai
Deal Date10 Dec 202513 Mar 20246 Dec 20239 Aug 2023
RoundSeedSeries ASeries ASeries A
Raisedundisclosed$14M$14M$14M
InvestorsZGC Group; Botanee GroupLizhong Investment; Botanee Group; CDH InvestmentsIDG Capital; Huajin Avenue Investment; Botanee Group; Woyong Fund; Sharewin Investment; CS CapitalSinopharm-CICC; Botanee Group; Sinovation Ventures
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Botanee Group investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Botanee Group

When was Botanee Group founded?Botanee Group was founded in 2010.
Where is Botanee Group headquartered?Botanee Group is headquartered in China.
How many employees does Botanee Group have?As of today, Botanee Group has over 4K employees.
Is Botanee Group publicly listed?Yes, Botanee Group is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Botanee Group?Botanee Group trades under 300957 ticker.
When did Botanee Group go public?Botanee Group went public in 2021.
Who are competitors of Botanee Group?Botanee Group main competitors include Flyco, Zydus Wellness, Anhui Anke Biotechnology, Emami, Harbin Fuerjia Technology, Alicorp, Softcare, Qingdao Baheal Medical, Kolmar Korea, Blue Moon Group.
What is the current market cap of Botanee Group?Botanee Group's current market cap is $2B.
What is the current revenue of Botanee Group?Botanee Group's last 12 months revenue is $841M.
What is the current revenue growth of Botanee Group?Botanee Group revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of Botanee Group?Current revenue multiple of Botanee Group is 1.8x.
What is the current EBITDA of Botanee Group?Botanee Group's last 12 months EBITDA is $130M.
What is Botanee Group's EBITDA margin?Botanee Group's last 12 months EBITDA margin is 15%.
What is the current EV/EBITDA multiple of Botanee Group?Current EBITDA multiple of Botanee Group is 11.4x.
What is the current FCF of Botanee Group?Botanee Group's last 12 months FCF is $46M.
What is Botanee Group's FCF margin?Botanee Group's last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Botanee Group?Current FCF multiple of Botanee Group is 32.3x.
How many companies Botanee Group has acquired to date?Botanee Group hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Botanee Group has invested to date?As of July 2026, Botanee Group has invested in 4 companies.
What was the last Botanee Group investment?On 10th December 2025 Botanee Group invested in Zisong Medical, participating in a Seed round, alongside ZGC Group.
In what companies Botanee Group invested in?Botanee Group invested in Weimu Medical, Weimai Medical, Ruishi Technology, and Zisong Medical.

See public comps similar to Botanee Group

Lists including Botanee Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial